Ultimovacs ASA's Phase II FOCUS trial (NCT05075122) investigating the UV1 universal cancer vaccine in combination with pembrolizumab did not meet its primary or secondary endpoints in patients with late-stage head and neck squamous cell carcinoma (HNSCC). The study, an investigator-sponsored trial led by Professor Mascha Binder at the University of Halle-Wittenberg in Germany, aimed to determine if adding UV1 to standard pembrolizumab treatment would improve clinical outcomes.
The topline data, now available on medRxiv, indicated that the combination did not lead to statistically significant clinical benefits in progression-free survival (PFS) or overall survival (OS) compared to pembrolizumab alone. The trial randomized 75 patients indicated for treatment with pembrolizumab in a 2:1 ratio, with 50 receiving UV1 plus pembrolizumab and 25 receiving pembrolizumab monotherapy.
Trial Design and Endpoints
The FOCUS trial was designed as a randomized, open-label Phase II study. The primary endpoint was the PFS rate at 6 months after the first administration of the study medication. Secondary endpoints included PFS, OS (assessed by Kaplan-Meier estimate), objective response rate (ORR), duration of response (DOR), and safety, with a minimum follow-up of 12 months.
Safety Profile
Despite the lack of efficacy, UV1 demonstrated a favorable safety profile, consistent with previous studies. The incidence of adverse events was similar in both the combination and monotherapy arms, and the vaccine was generally well-tolerated.
UV1 Mechanism of Action
UV1 is a universal cancer vaccine designed to stimulate a specific T cell response against telomerase, an enzyme present in the majority of cancer cells. The vaccine consists of long, synthetic peptides derived from the reverse transcriptase subunit of telomerase (hTERT). These peptides are designed to induce CD4+ T cells, which can provide inflammatory signals and T cell support believed to be crucial for triggering a robust anti-tumor immune response. Following intradermal injection with the immune-modulator GM-CSF, antigen-presenting cells (APCs) in the skin process the peptides and present vaccine epitopes on Human Leukocyte Antigen (HLA) molecules to naïve T cells in the lymph nodes. Activated vaccine-specific T cells then circulate and target cells displaying their cognate antigen in the context of HLA molecules. The UV1 peptides contain several epitopes, shown to be non-restrictive in terms of HLA alleles for presentation, potentially enabling broad population utilization without HLA pre-screening.
